Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia

Leuk Lymphoma. 2020 Apr;61(4):987-989. doi: 10.1080/10428194.2019.1689393. Epub 2019 Nov 14.

Authors

Michele Merli¹, Benedetta Bianchi¹, Lorenza Bertù¹, Andrea Ferrario¹, Barbara Mora¹, Daniela Furlan², Silvia Uccella², Fausto Sessa², Francesco Passamonti¹

Affiliations

¹ Department of Hematology, University Hospital "Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi", University of Insubria, Varese, Italy.
² Anatomic Pathology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy.

PMID: 31724890
DOI: 10.1080/10428194.2019.1689393

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Mutation
Myeloid Differentiation Factor 88 / genetics
Risk Assessment
Waldenstrom Macroglobulinemia* / diagnosis
Waldenstrom Macroglobulinemia* / epidemiology

Substances

Myeloid Differentiation Factor 88